TKT and cancer: The genetically engineered VV, Pexa-Vec (JX-594), targets cancer cells via multiple mechanisms, whereby virus replication is activated by EGFR/KRAS pathway signaling, cellular thymidine kinase (TK) levels, and resistance to type I interferons (IFNs) in cancer cells [42].